ArticleNPJ precision oncology2025

Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer.

Esther P B Rodman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.